节奏掌握得不错，高人_老虎社区_美港股上老虎 - 老虎社区

节奏掌握得不错，高人

金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":606172942,"tweetId":"606172942","gmtCreate":1638848163281,"gmtModify":1638848267324,"author":{"id":3486361727758741,"idStr":"3486361727758741","authorId":3486361727758741,"authorIdStr":"3486361727758741","name":"Rio999","avatar":"https://static.tigerbbs.com/c1e4178e32cb0fcff4b50f4dce9cc6b4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>节奏掌握得不错，高人</p></body></html>","htmlText":"<html><head></head><body><p>节奏掌握得不错，高人</p></body></html>","text":"节奏掌握得不错，高人","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/606172942","repostId":2189681957,"repostType":2,"repost":{"id":"2189681957","pubTimestamp":1638836079,"share":"https://www.laohu8.com/m/news/2189681957?lang=&edition=full","pubTime":"2021-12-07 08:14","market":"us","language":"zh","title":"金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2189681957","media":"AAFN","summary":"金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/01548\">金斯瑞生物科技</a>  公布，其非全资附属公司「<a href=\"https://laohu8.com/S/LEGN\">传奇生物</a>」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n金斯瑞生物科技(01548.HK)非全资附属向日本提交骨髓瘤新药申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 08:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","relate_stocks":{"BK1583":"高瓴概念","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","01548":"金斯瑞生物科技"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1147960&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2189681957","content_text":"金斯瑞生物科技  公布，其非全资附属公司「传奇生物」宣布，其合作夥伴杨森制药今天向日本厚生劳动省提交西达基奥仑赛的新药申请。西达基奥仑赛是一款在研的靶向B细胞成熟抗原嵌合抗原受体T细胞疗法，用於治疗复发或难治性多发性骨髓瘤成人患者。(na/w)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":663,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/606172942"}